University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Varespladib (A-002)
Drug: placebo

First Posted Date: 2007-09-21

Last Posted Date: 2009-10-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 164

Registration Number: NCT00533039

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Phase 1

Completed

Conditions: Cancer of the Cervix

Interventions: Drug: Sorafenib
Drug: Cisplatin
Procedure: Radiation

First Posted Date: 2007-08-01

Last Posted Date: 2015-07-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 13

Registration Number: NCT00510250

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)

Completed

Conditions: Breast Cancer

First Posted Date: 2007-07-12

Last Posted Date: 2016-03-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 372

Registration Number: NCT00500383

Locations: 🇨🇦
Juravinski Cancer Center, Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦
Women's College Hospital, Toronto, Ontario, Canada

and more 1 locations

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreas
Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2007-07-06

Last Posted Date: 2019-05-30

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 51

Registration Number: NCT00497224

Locations: 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 2 locations

The Effect of Radiation on Semen Quality and Fertility in Men With Prostate Cancer

Completed

Conditions: Prostate Cancer

First Posted Date: 2007-07-04

Last Posted Date: 2015-12-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT00496249

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Irinotecan
Drug: Capecitabine

First Posted Date: 2007-06-07

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 50

Registration Number: NCT00483834

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Sunitinib Malate (Sutent)

First Posted Date: 2007-05-31

Last Posted Date: 2015-12-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 3

Registration Number: NCT00480935

Locations: 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cytarabine

First Posted Date: 2007-05-30

Last Posted Date: 2019-02-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT00480090

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Metastatic Disease

Interventions: Drug: Sorafenib

First Posted Date: 2007-05-30

Last Posted Date: 2015-12-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT00480389

Locations: 🇨🇦
Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

Phase 2

Conditions: Type 2 Diabetes
Hypercholesterolemia

Interventions: Dietary Supplement: Cinnamonforce
Dietary Supplement: Placebo

First Posted Date: 2007-05-30

Last Posted Date: 2007-11-20

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 70

Registration Number: NCT00479973

Locations: 🇨🇦
UHN - Toronto Western Hospital, Toronto, Ontario, Canada
🇨🇦
Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy